Literature DB >> 9400601

A glycine to alanine substitution in the paramyxovirus SV5 fusion peptide increases the initial rate of fusion.

S Bagai1, R A Lamb.   

Abstract

Simian virus 5 fusion (F) protein mutant F-G3A, which contains a glycine-to-alanine substitution at position 3 in the conserved hydrophobic fusion peptide at the N-terminus of the F1 subunit, has been shown previously to cause increased syncytium formation compared to wild-type (wt) F protein, when expressed using an SV40 recombinant virus vector system (C. M. Horvath and R. A. Lamb (1992) J. Virol. 66, 2443-2455). The wt F and the F-G3A proteins were expressed in eukaryotic cells using the vaccinia virus-bacteriophage T7 RNA polymerase (vac-T7) expression system, and they showed similar cell surface expression levels as determined by flow cytometry. The final extent of fusion when the vac-T7 expression system was used was not found to be greatly different when examined with a reporter gene activation assay. However, the initial rate of fusion was found to be five- to sixfold higher for the F-G3A mutant protein than the wt F protein, when examined using a quantitative assay for lipid mixing based on relief of self-quenching of fluorescence of the lipid probe octadecyl rhodamine (R18). A microscopic fluorescent dye transfer assay also showed a much earlier spread of dye from R18-labeled red blood cells to the cells expressing the mutant F-G3A protein than the wt F protein. Thus, these data indicate that a single gly-to-ala mutation in the fusion peptide domain, although not affecting the final extent of fusion, significantly increased the rate of fusion. Possible mechanisms for the increased rate of fusion are discussed.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9400601     DOI: 10.1006/viro.1997.8858

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  8 in total

1.  Nonneutralizing Antibodies Induced by the HIV-1 gp41 NHR Domain Gain Neutralizing Activity in the Presence of the HIV Fusion Inhibitor Enfuvirtide: a Potential Therapeutic Vaccine Strategy.

Authors:  Qian Wang; Wenwen Bi; Xiaojie Zhu; Haoyang Li; Qianqian Qi; Fei Yu; Lu Lu; Shibo Jiang
Journal:  J Virol       Date:  2015-04-22       Impact factor: 5.103

2.  Full-length genome sequence of avain paramyxovirus type 4 isolated from a mallard duck.

Authors:  Woo-Jin Jeon; Eun-Kyoung Lee; Jun-Hun Kwon; Kang-Seuk Choi
Journal:  Virus Genes       Date:  2008-09-03       Impact factor: 2.332

3.  Flexibility of the Head-Stalk Linker Domain of Paramyxovirus HN Glycoprotein Is Essential for Triggering Virus Fusion.

Authors:  Emmanuel Adu-Gyamfi; Lori S Kim; Theodore S Jardetzky; Robert A Lamb
Journal:  J Virol       Date:  2016-09-29       Impact factor: 5.103

4.  Membrane fusion promoted by increasing surface densities of the paramyxovirus F and HN proteins: comparison of fusion reactions mediated by simian virus 5 F, human parainfluenza virus type 3 F, and influenza virus HA.

Authors:  R E Dutch; S B Joshi; R A Lamb
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

5.  Conserved glycine residues in the fusion peptide of the paramyxovirus fusion protein regulate activation of the native state.

Authors:  Charles J Russell; Theodore S Jardetzky; Robert A Lamb
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

6.  Parainfluenza Fusion Peptide Promotes Membrane Fusion by Assembling into Oligomeric Porelike Structures.

Authors:  Mariana Valério; Diogo A Mendonça; João Morais; Carolina C Buga; Carlos H Cruz; Miguel A R B Castanho; Manuel N Melo; Cláudio M Soares; Ana Salomé Veiga; Diana Lousa
Journal:  ACS Chem Biol       Date:  2022-05-02       Impact factor: 4.634

7.  Mutational analysis of the subgroup A avian sarcoma and leukosis virus putative fusion peptide domain.

Authors:  J W Balliet; K Gendron; P Bates
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

8.  A point mutation in the binding subunit of a retroviral envelope protein arrests virus entry at hemifusion.

Authors:  Tatiana Zavorotinskaya; Zhaohui Qian; John Franks; Lorraine M Albritton
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.